Pharmacy Resources Incorporated, Denver, CO
Is Pharmacy Resources Incorporated registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Pharmacy Resources Incorporated hold a Colorado pharmacy license?
The Colorado State Board of Pharmacy lists license PDO 370000012 for Pharmacy Resources Incorporated, Denver, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054017544 for PHARMACY RESOURCES INC, DENVER, CO, status NOT RENEWED, as of Nov 13, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000285 for Pharmacy Resources, Inc., Denver, CO, status Expired, as of Nov 10, 2026.
Has Pharmacy Resources Incorporated had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Mar 25, 2020) for Pharmacy Resources Incorporated. State board actions: no Colorado State Board of Pharmacy action on license PDO 370000012 or under this exact name and city was found in the board’s license dataset (actions dated Oct 11, 1985 to Oct 30, 2026) on Nov 15, 2026. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Aug 2, 2018, case AC 6021 on nonresident license NRP 1126.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Pharmacy Resources Incorporated
- Location
- Denver, CO
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Mar 25, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 OAI; 2 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 14 observations
- State board records
- License found: PDO 370000012, Expired
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pharmacy Resources Incorporated, a 503A facility, with 2 dated actions.
| Document | |||
|---|---|---|---|
| Mar 25, 2020 | FMD-145 letter | FMD-145 Letter Issued 03/25/2020 | FDA copy (archived) |
| Jan 29, 2019 | Form 483 | 483 Issued 01/29/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Pharmacy Resources Incorporated, Denver, CO (FEI number 3002946837), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jan 29, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3002946837 | 1077444 |
Form 483s FDA has published for this site
- Jan 29, 2019: Form 483 to Pharmacy Resources Incorporated, published Apr 30, 2019. fda.gov
- Aug 8, 2017: Form 483 to Pharmacy Resources Incorporated, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending May 23, 2017 to Jan 29, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jan 9, 2019 to Jan 29, 2019: 7 observations
- Firm on the cover
- Pharmacy Resources Incorporated, 5290 E Yale Cir Ste 101, Denver, CO 80222- 6927
- FEI number
- 3002946837
- Establishment type on the cover
- Producer of Sterile and Non- Sterile Drug Products
- FDA district office on the cover
- Denver, CO 80225- 0087
- Matched to this page by
- FEI number on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
Aseptic processing areas, which are used for production of sterile, intrathecal, and epidural drug product s fo r human use, consist of (b)(4) ISO-5 workstations located within an ISO-7 cleanroom. Personnel clean inside th e ISO- 5 workstation s (b)(4 ) with sterile water followed by (b)(4), personnel clean inside the ISO-5 workstations using either a sporicidal disinfectant or (b)(4), which alternate each (b)(4).Aseptic processing area s, which are used for production of sterile, intrathecal, and epidural drug products for human use, consist of (b)(4) ISO-5 workstations located within an ISO-7 cleanroom. Personnel clean inside the ISO-5 workstations (b)(4) with sterile water followed by (b)(4), personnel clean inside the ISO-5 workstations using either a sporicidal disinfectant or (b)(4), which alternate each (b)(4) .
Aseptic processing areas, which are used for production of sterile, intrathecal, and epidural drug products for human use, consist of (b)(4) ISO-5 workstations located within an ISO-7 cleanroom. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
Specifically,
Your film has not conducted in situ air pattern analyses (smoke studies) under conditions that simulate normal operating conditions in the cleanroom, laminar-flow hoods, and biosafety cabinet.
This is a repeat observation.
Observation 3
Specifically,
Other than sterile gloves, the garments and protective apparel w orn by sterile d rug technicians consist of non-s terile shoe covers, a non-sterile bouffant hair cover, a non-sterile face mask/shield, and a non-sterile (b)(4) outer gown, which is sprayed with non-sterile (b)(4) prior to donning.Other than sterile gloves, the garments and protective apparel worn by sterile drug technicians consist of non-sterile shoe covers, a non-sterile bouffant hair cover, a non-sterile face mask/shield, and a non-sterile (b)(4) outer gown, which is sprayed with non-sterile (b)(4) prior to donning.Other than sterile gloves, the garments and protective apparel worn by sterile drug technicians consist of non-sterile shoe covers, a non-sterile bouffant hair cover, a non-sterile face mask/shield, and a non-sterile (b)(4) outer gown, which is sprayed with non-sterile (b)(4) prior to donning.
On 10-Jan-19, during aseptic preparation of Tri-mix 30-3-30 injectable, lot 100119, expiration date 10-Feb-19, an employee with exposed hair and skin on the back of their neck was observed placing non-sterile sleeves inside the ISO-5 biosafety cabinet.
This is a repeat observation.
Observation 4
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Specifically,
Empty sterile vials used for sterile veterinary drugs are exposed to ISO-7 conditions prior to transfer to the ISO-5 w orkstation. For example, on 09-Jan-19, four (4) empty u ncovered, pre-sterilized 30-ml vials were observed on a cart location in the ISO-7 area adjacent to ISO-5 Hood (b)(4). The vials were subsequently transferred into Hood (b)(4) and Medroxy-Progesterone 100 mg/ml solution, lot 090119, was (b)(4) into the vials.Empty ste r ile vials used for sterile veterinary drugs are exposed t o ISO-7 conditions prior to transfer to the ISO-5 works tation. For example, on 09-Jan-19, four (4) empty uncovered, pre-sterilized 30-ml vials were observed on a cart location in the ISO-7 area adjacent to ISO-5 Hood (b)(4). The vials were subsequently transferred into Hood (b)(4) and Medroxy-Progesterone 100 mg/ml solution, lot 090119, was (b)(4) into the vials.Empty ste rile vials used for sterile veterinary drugs are exposed to ISO-7 conditions prior to transfer to the ISO-5 workstation. ...
Observation 5
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
Your firm does not have finished product sterility data to support the current expiration dates for finished drug products formulated from stock solutions.
For example, the current finished product expiration dates of 90 days for (b)(4) Tri-Mix Injectable, lot 061118, expiry 06-Feb-19, and Quad Mix (Standard) 9-1-0.1-10 Injectable, lot 061118, expiry 06-Feb-19, are supported with the following sterility data from the stock solutions (ingredients used to prepare each of the finished products above):
• Papaverme HCl 30 mg/cc: expiry date oflb> < 4f days is based upon (D) ("1-) I [(5) ("1-) 1. • Phentolamme Mesvlate 10 mg/cc: expiry date o((bH4) days is based upon [( D) (4) I [(5) ("1-) l • Prostaglandm E-1 (PGE-1) 500 mcg/ml expiry date of H4f days is based upon [(D) ("1-)
1(5) @) \ lDJ l4J
A (b)(4) step is performed when each of these stock solutions is combined to compound one of the final products above. ~b) (4A (b)(4) step is performed when each of these stock solutions is combined to compound one of the final products above. ...
Observation 6
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
The environmental monitoring program does not provide information about the aseptic processing environment during (b)(4) sterile operations. For example, viable monitoring (air, surface, and personnel) was not performed during the compounding of (b)(4) Tri-Mix injectable, lot 061118, expiration 06-Feb-19 or Quad Mix (Standard) 9-1-0.1-10 Injectable, lot 061118, expiration 06-Feb-19.
In addition:
A. Smface monitoring inside the IS0-5 workstations is conducted on a[(D) (4) Ibasis.
B. Air is not sampled inside the IS0-5 workstations during'(b) <4Yaseptic foimulation operations. For example:
• Air sampling (viable - settle plate) is conducted in the IS0-7 area on a(D) (4) Ibasis . • Air sampling (viable - active) is conducted inside the IS0-5 workstations eveiy 1(5) -(~2] during room qualification activities and is not completed during or immediately following steiile mug foimulation activities.
C. Personnel monit01ing is conducted I@) (4) I during employees' gowning re-qualification and media fill. Personnel monitoring only includes fingeitip sampling. ...
Observation 7
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that confirm to appropriate standards of identity, strength, quality and purity.
Specifically,
Method suitability testing has not been performed to determine if in-house sterility test methods used for final product testing of sterile erectile dysfunction (ED) Drugs are effective at recovering organisms from final
Compounded products. For example, Quad Mix (standard) 9-1-0.1-10, lot 061118, expiry 06-Feb-19, is formulated with (b)(4); however, method suitability testing has not been performed to demonstrate the in-house sterility method is capable of recovering organisms in the presence of product. Compounded products. For example, Quad Mix (standard) 9-1-0.1-10, lot 061118, expiry 06-Feb-19, is formulated with (b)(4); however, method suitability testing has not been performed to demonstrate the in-house sterility method is capable of recovering organisms in the presence of product. Compounded products. ...
Inspection May 8, 2017 to May 23, 2017: 7 observations
- Firm on the cover
- , 5290 East Yale Circle, Ste 101 Pharmacy Resou rces Incorporated, Denver, co 80222
- FEI number
- 3002946837
- Establishment type on the cover
- Producer of St erile and Non- St erile Drugs
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room equipment to produce aseptic conditions.
and
Specifically,
Your firm's cleaning agents are not adequate for use in your ISO 5 LAFW and ISO 7 clean room.
A. On 5/8/17, I observed a bottle of expired REDACTED (B) (4) (sporicidal agent) in the pharmacy's storage cabinet. The REDACTED (b)(4) was expired as of 9/29/15.
B. In addition, disinfectant efficacy has not been established for the REDACTED (b)(4) and the REDACTED (b)(4) used to clean the inside of the ISO 5 LAFW on REDACTED (b)(4) basis. For example, there is no scientific justification for the current REDACTED (b)(4) contact time established for both of your sanitizing agents. For sporicidal activity, the REDACTED (b)(4) sanitizer labeling requires an undiluted chemical contact time of REDACTED (b)(4). (4) J
In addition, during the inspectional walk-through of your facility on 5/8/17, non-smooth cleaning surfaces (porous speakers) were observed in the ISO 7 ce1iified cleanroom/buffer ru.·ea to include a small stereo and an intercom system.
Observation 2
Aseptic processing areas ar e deficient regarding the system for monitoring environmental conditions.
Specifically,
1) Environmental monitoring perfo1med by your fom is not representative of continued daily sterile
operations. Viable (air, surface, and personnel) monitoring was not perfo1med during the compounding of Tri-Mix Injectable, Lot Number: 080517. For example: C. Personnel monitoring only occurs REDACTED (b)(4) during REDACTED (b)(4) and only includes REDACTED (b) (4). This is not representative of the daily sterile operations or the batches of sterile product produced at the facility.
D.Viable monitoring is not performed more frequently than during the REDACTED (b)(4) and is completed REDACTED (b) (4). This is not representative of the daily sterile operations.
E. Surface and air microbial monitoring of the ISO 5 areas are only perfo1med on REDACTED (b)(4) basis which is not representative of the daily sterile operations.
F. Review of 2016 and 2017 REDACTED (b)(4) environmental monitoring data, which docum
ented surface and air microbial results, identified positive results that were never investigate d, to include:
a. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products pur porting to be sterile do not include adequate validation of the sterilization process.
Specifically,
Your firm has not conducted in situ air pattern analyses (smoke studies) under dynamic conditions, simulating routine production in the cleanroom and the laminar-flow hoods and REDACTED (b)(4). Without, there is no assurance critical processing areas are suitable for aseptic manufacturing of sterile drng products.
Observation 4
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
Your firm does not have any finished product sterility data to support the current expiration dates for any of the erectile dysfunction sterile drug products.
For example, the current finished product expiration dates of 90 days for Tri-Mix and Bi-Mix, and 60 days for Super Tri-Mix and QuadMix injectables, are only supplied with the following sterility data from the stock solutions (ingredients used to prepare each of the finished products above):
REDACTED (b)(4) expiry date of REDACTED (b)(4) days is based uponREDACTED (b)(4) . REDACTED (b)(4) expiiy date of REDACTED (b)(4) days is based upon REDACTED (b)(4) . No sterility data is available at REDACTED (b)(4) timeframe. REDACTED (b)(4) expiry date of REDACTED (b)(4) days is based upon REDACTED (b)(4). Sterility has only been determined at REDACTED (b)(4). In addition, there is no sterilization step when each of these stock solutions is combined to compound one of the final products above.
Observation 5
Protective apparel is not worn as necessary to protect diug products from contamination.
Specifically, the garments and protective apparel worn by your sterile drug technicians are inadequate. Your clean room gowning consists of non-sterile shoe covers, non-sterile hair- net, non-sterile face mask/shield, a day use sterile outer gown, and sterile gloves. On 5/8/17, I observed your technician wearing the above non-sterile clean room garb while performing aseptic filling of Tri-Mix, Lot # 080517 in the ISO 5 zone.
Observation 6
Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically,
All of your firm's erectile dysfunction sterile drug products are tested for sterility with an in-house method. However, sterility testing by your laboratory does not meet all the requirements for sampling and method suitability specified in relevant compendial methods.
For example, a method suitability test (a positive control using different challenge microorganisms to demonstrate that the dilution/recovery scheme used is effective at neutralizing any residual antimicrobial properties of the compound) is not conducted for any of the erectile dysfunction formulations.
Observation 7
Routine calibration of equipment is not performed according to a written program designed to assure proper performance.
Specifically, there is a failure to calibrate equipment used in the production of sterile drug products, for example:
A)The REDACTED (b)(4) used to perform REDACTED (b)(4) after the compounding of sterile products has been due for calibration since December 31 , 2015; I
B) The REDACTED (b)(4) that is used to REDACTED (b)( 4) used during the sterile production of both animal and human sterile drug compounds has not been calibrated, to include calibration of the REDACTED (b)(4) .
C) The REDACTED (b)(4) that is u sed to REDACTED (b)(4) sterilize compounded equine animal drug products as well as the REDACTED (b) (4) d rug produ ct, REDACTED (b)(4) with REDACTED (b)(4) has not been calibrated, to incl ude cali bra tion of the REDACTED (b)(4).
Linked 483s whose text is not shown
- Jan 29, 2019: FDA document 120799: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
The Colorado State Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PDO 370000012 | PDO | Pharmacy Resources Incorporated | Denver | Expired |
What this covers: Discipline the Department of Regulatory Agencies publishes with each license in the dataset (case number, program action and effective date), worded as the department gives it. Actions in the data are dated Oct 11, 1985 to Oct 30, 2026.
Nonresident licenses and board actions in other states
These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
- Aug 2, 2018: “Through a disciplinary action of the Board, the license is voluntarily surrendered.”, license NRP 1126, case AC 6021, Pharmacy Resources, Denver, CO. Board list
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054017544 | LICENSED PHARMACY | PHARMACY RESOURCES INC | DENVER, CO | NOT RENEWED |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0000285 | Non Resident Pharmacy | Pharmacy Resources, Inc. | Denver, CO | Expired |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Delaware Division of Professional Regulation license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.